Comparative Pharmacology
Head-to-head clinical analysis: ENULOSE versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENULOSE versus XPHOZAH.
ENULOSE vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic pH and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
15-45 mL orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 mL per day.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category C
Category C
Laxative
Laxative